Korean J Clin Pathol.  2000 Apr;20(2):126-131.

Establishing Therapeutic Ranges of Activated Partial Thromboplastin Time for Heparin Therapy using Anti-Xa Activity

Affiliations
  • 1Department of Clinical Pathology, College of Medicine, Yonsei University, Seoul, Korea.

Abstract

BACKGROUND: The commonly recommended therapeutic range is an activated partial thromboplastin time(APTT) of 1.5 to 2.5 times the control value, which may be inappropriate for some reagents. The aim of this study is to evaluate the correlation of APTT and anti-Xa activity and to compare two methods of determining the therapeutic range of APTT during unfractionated heparin treatment.
METHODS
We measured anti-Xa activity and APTT in 80 plasmas from patients treated with unfractionated heparin. We performed correlation analysis between anti-Xa activity and APTT or APTT ratio(heparinized APTT/baseline APTT). The therapeutic range determined by anti-Xa activity of 0.35-0.7 U/mL was compared with the therapeutic range based on minimizing potential thrombosis and bleeding error.
RESULTS
The anti-Xa activity-vs-APTT correlation was slightly, but not significantly, improved by converting APTT(r=0.835) to APTT ratio(r=0.883). The APTT therapeutic range predicted by anti-Xa activity-vs-APTT regression analysis was 68.7 to 139.5 seconds(66.6-127.9 seconds for logarithmatically transformed APTT), whereas the range predicted by minimization-of-error technique was 68 to 97 seconds.
CONCLUSIONS
The established therapeutic APTT range based on linear regression analysis was not considered to be optimal. The therapeutic range based on minimizing the potential clinical errors may further improve error rate, but prospective study with a larger number of patient samples would be required to apply in clinical field.

Keyword

Unfractionated heparin; Anti-Xa activity; Therapeutic range

MeSH Terms

Hemorrhage
Heparin*
Humans
Indicators and Reagents
Linear Models
Partial Thromboplastin Time*
Plasma
Thromboplastin
Thrombosis
Heparin
Indicators and Reagents
Thromboplastin
Full Text Links
  • KJCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr